The Australian Government has expanded eligibility for the osteoporosis medication alendronate under the Pharmaceutical Benefits Scheme (PBS).
From 1_April_2007, alendronate (in the form of Fosamax? Once Weekly and Alendro? Once Weekly) will be available on the PBS for patients with osteoporosis aged 70 years and over who are at high risk of fracture as measured by a bone mineral density test. Alendronate is already available on the PBS for patients with osteoporosis who have suffered a bone fracture following minimal trauma, but the new measure may help prevent fractures occurring in the first place. Alendronate belongs to a class of drugs that strengthen bones and prevent fractures by increasing bone mineral density.
To coincide with this expanded eligibility for alendronate, bone mineral density tests for all patients aged 70 years and over will be covered by Medicare from 1 April 2007. The bone mineral density test is currently subsidised through Medicare for patients who have proven indications of low bone mineral density, have an underlying condition or are on a course of treatment that can cause low bone mineral density.
Nearly two million Australians have osteoporosis. Osteoporosis occurs when bones lose minerals such as calcium. Bones become fragile and brittle, leading to a higher risk of fractures than normal bone. Fractures can lead to long-term pain and disability, loss of independence and can contribute to premature death. An adequate daily intake of calcium combined with the vitamin D received from moderate sunlight exposure are important in reducing the impact of osteoporosis.